Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pfizer introduces oral SARS-CoV-2 inhibitor

By Brian Buntz | April 8, 2021

PfizerAn experimental oral antiviral from Pfizer that recently became the focus of a Phase 1 study was featured at the American Chemical Society Spring 2021 meeting.

Known as PF-07321332, the compound is a protease inhibitor. It works by binding to a viral enzyme known as protease to block viral replication.

Protease inhibitors are used to treat HIV/AIDS and hepatitis C, but PF-07321332 is the first oral protease inhibitor to target the SARS-CoV-2 virus.

Protease inhibitors are generally well tolerated. Side effects of protease inhibitors, in general, can include diarrhea, nausea and vomiting and insulin resistance.

Pfizer has also developed PF-07304814, a similar protease inhibitor, but that compound is intended for intravenous use.

Eli Lilly and Regeneron have developed infusion-based SARS-CoV-2 antibody drugs, but they have not been broadly used.

PF-07321332, if authorized, could be prescribed when the first symptoms of COVID-19 emerge.

Pfizer created PF-07321332 during the pandemic, first synthesizing it in July 2020.

In later tests, the compound displayed strong in vitro antiviral activity against SARS-CoV-2 and other coronaviruses.

Its broad-spectrum efficacy could make it effective against future coronavirus-associated pandemics.

Pfizer estimates that the Phase 1 trial of the drug will be completed by May 30.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: clinical trials, coronavirus, covid-19, PF-07321332, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer
Pfizer shares positive top-line data from Phase 3 Study of pneumococcal vaccine
Vaccine
The most common monkeypox vaccine side effects
FDA logo
FDA grants emergency use authorization to Jynneos monkeypox vaccine to support ‘dose sparing’
JYNNEOS vaccine
Jynneos vaccine: The best weapon against monkeypox?

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50